The direct and indirect effects of Coronavirus Disease-19 (COVID-19) pandemic, on Italian patients with lysosomal storage disorders receiving therapy, were analyzed by a phone questionnaire. No proved COVID-19 emerged among 102 interviewed. No problems were reported by patients receiving oral treatments. Forty-nine% of patients receiving enzyme replacement therapy in hospitals experienced disruptions, versus 6% of those home-treated. The main reasons of missed infusions were fear of infection (62.9%) and re-organization of the infusion centers (37%).

中文翻译：

---

意大利首次体验到与COVID-19相关的医疗危机对溶酶体贮积症患者的治疗的影响。

通过电话问卷分析了冠状病毒病19（COVID-19）大流行对接受治疗的意大利溶酶体贮积症患者的直接和间接影响。在102位受访者中，没有证实有COVID-19出现。接受口服治疗的患者未报告任何问题。在医院接受酶替代疗法的患者中，有49％经历了干扰，而在家接受治疗的患者则为6％。输液失败的主要原因是害怕感染（62.9％）和输液中心的重组（37％）。